Claim and source comparison

Comparison scope: Pandit 2016 methods/results and Table 2; abstracts of Biswas 2010, Stohs 2014 and Kamgar 2025. Not a complete clinical or independent medical review.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Human randomized controlled trial

Pandit 2016: 96 men aged 45–55 were randomized; 38 shilajit and 37 placebo participants completed. With purified product at 250 mg twice daily for 90 days, total testosterone increased 20.45% and free testosterone 19.14% relative to the group's own baseline.

These percentages are not additional increases over placebo. Data from 21 noncompleters were excluded from calculations. A hormone outcome is not cognitive benefit, prevention of aging or equivalence of all products; the accessed sections were methods and results.

Source 1 · Full text read

Uncontrolled human intervention study

Biswas 2010: 35 men with oligospermia received processed shilajit at 100 mg twice daily for 90 days; 28 completed. The 61.4% increase in total sperm count was relative to baseline.

The abstract has no concurrent control group. Change from baseline does not establish superiority to placebo, pregnancy/live-birth success or cognitive benefit; unchanged liver/kidney tests do not guarantee general safety.

Source 2 · Abstract read

Narrative review

Stohs 2014: A narrative review considers human, animal and laboratory studies together; it notes few well-controlled human studies and the need for more research with standardized products.

The review is not a new randomized trial or systematic effect estimate. ATP, fulvic-acid or hormone mechanisms do not establish clinical brain benefit or long-term safety of all products.

Source 3 · Abstract read

Cell / laboratory study

Kamgar 2025: Chemical analysis found more thallium in some shilajit supplements than in crude samples. The highest supplement value was 0.5 µg/g; the highest calculated intake from one pill was 0.095 µg.

µg/g is concentration; µg/pill is exposure, not a safe upper limit. This analysis does not measure human poisoning frequency; a purified label does not prove purity. Medicines, diabetes, iron overload, hormone-sensitive conditions or pregnancy require clinical assessment; missing interaction records do not establish safety.

Source 4 · Abstract read

Our evidence and source methodology

shilajit: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

Purified shilajit has been investigated for hormonal measures in specific small human trials. It is not an established general treatment for brain energy, mineral deficiency or CoQ10 bioavailability; purity and long-term safety matter.

Clinical Trials

Pandit 2016: 96 men aged 45–55 were randomized; 38 shilajit and 37 placebo participants completed. With purified product at 250 mg twice daily for 90 days, total testosterone increased 20.45% and free testosterone 19.14% relative to the group's own baseline.

These percentages are not additional increases over placebo. Data from 21 noncompleters were excluded from calculations. A hormone outcome is not cognitive benefit, prevention of aging or equivalence of all products; the accessed sections were methods and results.

Biswas 2010: 35 men with oligospermia received processed shilajit at 100 mg twice daily for 90 days; 28 completed. The 61.4% increase in total sperm count was relative to baseline.

The abstract has no concurrent control group. Change from baseline does not establish superiority to placebo, pregnancy/live-birth success or cognitive benefit; unchanged liver/kidney tests do not guarantee general safety.

Stohs 2014: A narrative review considers human, animal and laboratory studies together; it notes few well-controlled human studies and the need for more research with standardized products.

The review is not a new randomized trial or systematic effect estimate. ATP, fulvic-acid or hormone mechanisms do not establish clinical brain benefit or long-term safety of all products.

Kamgar 2025: Chemical analysis found more thallium in some shilajit supplements than in crude samples. The highest supplement value was 0.5 µg/g; the highest calculated intake from one pill was 0.095 µg.

µg/g is concentration; µg/pill is exposure, not a safe upper limit. This analysis does not measure human poisoning frequency; a purified label does not prove purity. Medicines, diabetes, iron overload, hormone-sensitive conditions or pregnancy require clinical assessment; missing interaction records do not establish safety.

Dose information and research limits

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

Sources

  1. Pandit S, et al. (2016). Clinical evaluation of purified Shilajit on testosterone levels in healthy volunteers. Andrologia, 48(5), 570–575. PubMed · PMID 26395129
  2. Biswas TK, et al. (2010). Clinical evaluation of spermatogenic activity of processed Shilajit in oligospermia. Andrologia, 42(1), 48–56. PubMed · PMID 20078516
  3. Stohs SJ. (2014). Safety and efficacy of shilajit (mumie, moomiyo). Phytotherapy Research, 28(4), 475–479. PubMed · PMID 23733436
  4. Kamgar E, et al. (2025). Quantifying of thallium in Shilajit and its supplements to unveil the potential risk of consumption of this popular traditional medicine. BMC chemistry, 19(1), 20. PubMed · PMID 39827344

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions